FO could activate transcription factors which control metabolic pathways in a tissue specific manner regulating nutrient traffic and reducing plasma TG. In addition, FO increases extracellular lipolysis by lipoprotein lipase (LpL) in adipose, heart and skeletal muscle and enhances hepatic and skeletal muscle β-oxidation which contributes to reduced FA delivery to the liver. FO counteracts intracellular lipolysis in adipocytes by suppressing adipose tissue inflammation.

The key regulator of plasma NEFA is intracellular adipocyte lipolysis via hormone sensitive lipase (HSL), which increases as insulin sensitivity worsens. Thus reducing NEFA delivery to the liver would be a likely locus of action for fish oils (FO). Of these, NEFAs contribute the largest fraction to VLDL-TG production in both normotriglyceridemic subjects and hypertriglyceridemic, insulin resistant patients. The liver derives FAs from three sources: diet (delivered via chylomicron remnants), de novo lipogenesis, and circulating non-esterified FAs (NEFAs). Numerous mechanisms have been shown to contribute to the TG overproduction, but a key component is an increase in the availability of FAs in the liver. At the pharmaceutical dose, 3.4 g/day, they reduce plasma TG by about 25-50% after one month of treatment, resulting primarily from the decline in hepatic very low density lipoprotein (VLDL-TG) production, and secondarily from the increase in VLDL clearance. GSK is one of the top players in the healthcare and pharmaceutical industry can contribute to improving the healthcare sector of these markets (Lowson 26-34).Long chain omega-3 fatty acids (FAs) are effective for reducing plasma triglyceride (TG) levels.

Most of the third world countries are also approving of FDI for strengthening the internal social care prospects of their country. On the social sphere also, people are more concerned about their health care, needs and requirements that are increasing the scope of operations for GSK (Drummond, Ensor and Ashford 113-136). GSK already has a large network for markets can focus on creating mergers and acquisitions for enhancing their brand value in the market (Drogendijk and Hadjikhani 94). Opportunities: Globalization has created a better platform for business firms to engage in overseas business. GSK products have also sued for patent expiry cases which reduced the value of their international holdings considerably. Controversies relating to the composition and safety of drugs hamper the organizational brand equity in the overseas and domestic markets (Drummond, Ensor and Ashford 113-136). Weaknesses: The primary weakness of GSK is regarding their brand image. They have a high international presence with operations being conducted over 100 countries around the world and have a direct employee base of almost 98000 employees (GSK, “About us”). They were also awarded the Chemical Industry Manufacturing and Resource Efficiency Award increasing their brand value and brand equity in the international market (Lowson 26-34). They are also highly involved in the Research and Development investments which provide them the edge in the innovation of products. Analysis of GlaxoSmithKline: SWOT Strengths: GlaxoSmithKline is one of the biggest names in the global pharmaceutical industry and is counted among the top five pharmaceutical companies (About us, GSK.com).

Glaxo smith scotts emulsion